Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind double-dummy active-controlled study of anaprazole sodium enteric-coated tablets in adult reflux esophagitis
CTR20252165Phase 3Completed
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anaprazole sodium in erosive esophagitis (EE), sponsored by Xuanzhu Biopharmaceutical. Started Jul 2025; status: completed.
02
Drugs
anaprazole sodium
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on CTR20252165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252165.